These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Badger AM; Olivera DL; Esser KM Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060 [TBL] [Abstract][Full Text] [Related]
4. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Blease K; Burke-Gaffney A; Hellewell PG Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364 [TBL] [Abstract][Full Text] [Related]
5. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Seldon PM; Barnes PJ; Meja K; Giembycz MA Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903 [TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Turner CR; Esser KM; Wheeldon EB Circ Shock; 1993 Mar; 39(3):237-45. PubMed ID: 8384094 [TBL] [Abstract][Full Text] [Related]
8. Regulation of IL-15-stimulated TNF-alpha production by rolipram. Kasyapa CS; Stentz CL; Davey MP; Carr DW J Immunol; 1999 Sep; 163(5):2836-43. PubMed ID: 10453029 [TBL] [Abstract][Full Text] [Related]
9. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429 [TBL] [Abstract][Full Text] [Related]
10. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Genain CP; Roberts T; Davis RL; Nguyen MH; Uccelli A; Faulds D; Li Y; Hedgpeth J; Hauser SL Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3601-5. PubMed ID: 7536938 [TBL] [Abstract][Full Text] [Related]
11. Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Tam FW; Smith J; Agarwal S; Karkar AM; Morel D; Thompson EM; Pusey CD Nephron; 2000 Jan; 84(1):58-66. PubMed ID: 10644909 [TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. Eigler A; Siegmund B; Emmerich U; Baumann KH; Hartmann G; Endres S J Leukoc Biol; 1998 Jan; 63(1):101-7. PubMed ID: 9469479 [TBL] [Abstract][Full Text] [Related]
13. [Suppression of synthesis of tumor necrosis factor]. Eigler A; Loher F; Endres S Internist (Berl); 2001 Jan; 42(1):28-34. PubMed ID: 11271618 [TBL] [Abstract][Full Text] [Related]
14. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Miotla JM; Teixeira MM; Hellewell PG Am J Respir Cell Mol Biol; 1998 Mar; 18(3):411-20. PubMed ID: 9490659 [TBL] [Abstract][Full Text] [Related]
15. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes. Seldon PM; Barnes PJ; Giembycz MA Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245 [TBL] [Abstract][Full Text] [Related]
17. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495 [TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils. Meliton AY; Muñoz NM; Lambertino A; Boetticher E; Learoyd J; Zhu X; Leff AR Eur Respir J; 2006 Nov; 28(5):920-8. PubMed ID: 16807266 [TBL] [Abstract][Full Text] [Related]
19. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis. Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165 [TBL] [Abstract][Full Text] [Related]
20. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis. Taguchi I; Oka K; Kitamura K; Sugiura M; Oku A; Matsumoto M Inflamm Res; 1999 Jul; 48(7):380-5. PubMed ID: 10450787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]